Trial Profile
Phase III randomized double blind placebo-controlled trial of FavId and GM-CSF versus placebo and GM-CSF following rituximab in subjects with follicular B-cell non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitumprotimut T (Primary) ; Rituximab; Sargramostim
- Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- 04 May 2009 Full results have been reported in the Journal of Clinical Oncology.
- 09 Apr 2008 Data analysis and unblinding is expected in June 2008 according to a Favrille media release.
- 19 Feb 2008 Favrille have reported that data collection is on schedule with the final analysis expected no later than July 2008.